Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T57361
|
||||
Former ID |
TTDR00005
|
||||
Target Name |
Kallikrein
|
||||
Target Type |
Successful
|
||||
Disease | Peptic ulcer [ICD9: 531-534; ICD10: K25-K27] | ||||
Retinal venous occlusion [ICD10: H34.8] | |||||
Target Validation |
T57361
|
||||
Drugs and Mode of Action | |||||
References | |||||
Ref 522774 | ClinicalTrials.gov (NCT00969293) Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion. U.S. National Institutes of Health. | ||||
Ref 533503 | A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48. | ||||
Ref 533716 | J Med Chem. 1995 Apr 28;38(9):1511-22.Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.